-
公开(公告)号:US20250134978A1
公开(公告)日:2025-05-01
申请号:US18807315
申请日:2024-08-16
Applicant: ModernaTX, Inc.
Inventor: Nicholas Valiante , Ted Ashburn , Kristen Hopson
Abstract: The disclosure relates to cancer ribonucleic acid (RNA) vaccines, as well as methods of using the vaccines and compositions comprising the vaccines. In particular, the disclosure relates to concatemeric mRNA cancer vaccines encoding several cancer epitopes on a single mRNA construct, i.e. poly-epitope mRNA constructs or poly-neo-epitope constructs. The disclosure further relates to p53 and KRAS mutations, as well as incorporation of immune enhancers such as STING, e.g. mRNA constructs further encoding an immune stimulator or adjuvant. The disclosure further relates to inclusion of universal T cell epitopes, such as tetanus or diphtheria toxins to elicit an enhanced immune response.
-
公开(公告)号:US20210268086A1
公开(公告)日:2021-09-02
申请号:US17255949
申请日:2019-06-27
Applicant: ModernaTX, Inc.
Inventor: Shan Zhong , Benjamin Breton , Iain Mcfadyen , Kristen Hopson , Vincent Luczkow , Maija Garnaas
Abstract: The disclosure relates to optimized cancer vaccines, as well as methods of making the vaccines, using the vaccines, and compositions comprising the vaccines. The cancer vaccines comprise personalized cancer antigens or portions of cancer hotspot antigens. Additionally, the disclosure relates to a computerized system for selecting nucleic acids to include in an optimized cancer vaccine.
-
公开(公告)号:US20220236253A1
公开(公告)日:2022-07-28
申请号:US17615202
申请日:2020-05-29
Applicant: ModernaTX, Inc.
Inventor: Kristen Hopson
Abstract: Assays for assessing the therapeutic efficacy of vaccines, including personalized cancer vaccines are provided. Improved mRNA vaccines are also provided.
-
公开(公告)号:US20220125899A1
公开(公告)日:2022-04-28
申请号:US17291947
申请日:2019-11-07
Applicant: ModernaTX, Inc.
Inventor: Ted Ashburn , Kristen Hopson , Karen Keating , Joseph Senn , Christine Swenson , Benjamin Breton , Shan Zhong , Maija Garnaas
IPC: A61K39/00 , A61K39/395 , A61K9/51 , A61K31/7105 , A61K48/00 , A61P35/00 , C07K16/28
Abstract: The present application is related to a method of treating a cancer by administering to a human subject multiple doses of a mRNA cancer vaccine formulated as a lipid nanoparticle wherein the cancer vaccine comprises one or more mRNAs each having one or more open reading frames encoding 3-50 peptide epitopes, and wherein each of the peptide epitopes are portions of personalized cancer antigens or portions of cancer hotspot antigens. The present application further relates to a method of treating cancer by combining anti-cancer immunotherapy with the administration of the aforementioned mRNA cancer vaccine.
-
-
-